Gerovital
A controversial anti-aging treatment
Gerovital, also known as GH3, is a formulation developed in the mid-20th century by the Romanian scientist Ana Aslan. It is primarily known for its purported anti-aging properties and has been the subject of both interest and controversy in the medical community.
History[edit]
Gerovital was developed in the 1950s by Ana Aslan, a Romanian physician and biologist. Aslan was a pioneer in the field of gerontology, the study of aging and its effects. She believed that Gerovital could slow down the aging process and improve the quality of life for the elderly. The formulation gained popularity in Romania and other parts of Europe, attracting attention from celebrities and political figures.
Composition[edit]
Gerovital is based on the compound procaine, a local anesthetic. The formulation includes procaine hydrochloride, along with other ingredients such as benzoic acid and potassium metabisulfite. The exact mechanism by which Gerovital is claimed to exert its effects is not well understood, but it is believed to involve the stabilization of cell membranes and the improvement of cellular metabolism.
Claims and Uses[edit]
Proponents of Gerovital claim that it can reduce the effects of aging, improve mental clarity, and enhance overall vitality. It has been marketed as a treatment for a variety of conditions, including arthritis, depression, and hypertension. However, these claims are largely anecdotal, and scientific evidence supporting the efficacy of Gerovital is limited.
Controversy[edit]
The use of Gerovital has been controversial, particularly in the United States and other countries where it is not approved by regulatory agencies such as the Food and Drug Administration (FDA). Critics argue that there is insufficient scientific evidence to support the claims made about Gerovital, and concerns have been raised about its safety and potential side effects.
Current Status[edit]
Despite the controversy, Gerovital continues to be used in some countries, particularly in Eastern Europe. It is available in various forms, including injections, tablets, and creams. In recent years, interest in Gerovital has waned as more advanced and scientifically validated anti-aging treatments have become available.
Related pages[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian